中国病理性近视的临床特征,视觉质量及治疗现状的多中心研究

注册号:

Registration number:

ChiCTR1900024347 

最近更新日期:

Date of Last Refreshed on:

2019-07-06 20:33:50 

注册时间:

Date of Registration:

2019-07-06 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

中国病理性近视的临床特征,视觉质量及治疗现状的多中心研究

Public title:

A multicentre study for the clinical features, visual quality and treatment of pathological myopia in China

注册题目简写:

English Acronym:

研究课题的正式科学名称:

中国病理性近视的临床特征,视觉质量及治疗现状的多中心研究

Scientific title:

A multicentre study for the clinical features, visual quality and treatment of pathological myopia in China

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

许梅萍 

研究负责人:

瞿佳 

Applicant:

Meiping Xu 

Study leader:

Jia Qu 

申请注册联系人电话:

Applicant telephone:

+86 13587415286

研究负责人电话:

Study leader's
telephone:

+86 13806898805

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

suzen.0804@163.com

研究负责人电子邮件:

Study leader's E-mail:

jqu@wz.zj.cn

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

浙江省温州市鹿城区学院西路270号

研究负责人通讯地址:

浙江省温州市鹿城区学院西路270号

Applicant address:

270 Xueyuan Road West, Wenzhou, Zhejiang, China

Study leader's address:

270 Xueyuan Road West, Wenzhou, Zhejiang, China

申请注册联系人邮政编码:

Applicant postcode:

325027

研究负责人邮政编码:

Study leader's postcode:

325027

申请人所在单位:

温州医科大学附属眼视光医院

Applicant's institution:

Affiliate Eye hospital of Wenzhou Medical University

研究负责人所在单位:

温州医科大学附属眼视光医院

Affiliation of the Leader:

Affiliate Eye hospital of Wenzhou Medical University

是否获伦理委员会批准:

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

2019-018-K-18-02

伦理委员会批件附件:

Approved file of Ethical Committee:

批准本研究的伦理委员会名称:

温州医科大学附属眼视光医院伦理委员会

Name of the ethic committee:

Ethics Committee of the Affiliate Eye hospital of Wenzhou Medical University

伦理委员会批准日期:

Date of approved by ethic committee:

2019-07-04 00:00:00

伦理委员会联系人:

王晨晓

Contact Name of the ethic committee:

Chenxiao Wang

伦理委员会联系地址:

浙江省温州市鹿城区学院西路270号

Contact Address of the ethic committee:

270 Xueyuan Road West, Wenzhou, Zhejiang, China

伦理委员会联系人电话:

Contact phone of the ethic committee:

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

温州医科大学附属眼视光医院、北京大学人民医院

Primary sponsor:

Affiliate Eye hospital of Wenzhou Medical University; Peking University People's Hospital

研究实施负责(组长)单位地址:

浙江省温州市鹿城区学院西路270号、北京市西直门南大街11号

Primary sponsor's address:

270 Xueyuan Road West, Wenzhou, Zhejiang, China; 11 Xizhimen Street, Beijing, China

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

浙江省

市(区县):

温州市

Country:

China

Province:

Zhejiang

City:

单位(医院):

温州医科大学附属眼视光医院

具体地址:

浙江省温州市学院西路270号

Institution
hospital:

Affiliate Eye hospital of Wenzhou Medical University

Address:

270 Xueyuan Road West, Wenzhou, Zhejiang, China

国家:

中国

省(直辖市):

北京市

市(区县):

Country:

China

Province:

Beijing

City:

单位(医院):

北京大学人民医院

具体地址:

北京市西直门大街11号

Institution
hospital:

Peking University People's Hospital

Address:

11 Xizhimen Street, Beijing, China

经费或物资来源:

成都康弘生物科技有限公司

Source(s) of funding:

Chengdu Kanghong Biotechnology Co., Ltd.

研究疾病:

病理性近视  

Target disease:

Pathologic Myopia

研究疾病代码:

Target disease code:

研究类型:

观察性研究

Study type:

Observational study

研究所处阶段:

其它 

Study phase:

N/A

研究设计:

非随机对照试验 

Study design:

Non randomized control 

研究目的:

(1)基于医院的病理性近视的患病情况,临床特征和视觉质量相关性研究。 (2)分析中国病理性近视并发的脉络膜新生血管抗VEGF治疗现状和疗效。  

Objectives of Study:

(1) To study the correlation between clinical features and visual quality of pathological myopia, which is based on the hospital morbidity in China; (2) To analyze the current status and efficacy of anti-vascular therapy of choroidal neovascularization in pathological myopia in China.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

Inclusion criteria

排除标准:

既往眼外伤或者内眼手术史(白内障手术除外);
对检查欠合作,无法获得按要求的影像学资料和相关病历资料的患者;
合并明显的精神状态异常,存在沟通或者学习障碍者。

Exclusion criteria:

1. History of previous eye trauma or internal eye surgery (except cataract surgery);
2. Patients who do not cooperate with the examination can not obtain the required imaging data and related medical records;
3. Suffered with obvious mental disorders, communication or learning disabilities.

研究实施时间:

Study execute time:

From 2019-09-01 00:00:00 To 2021-08-31 00:00:00  

征募观察对象时间:

Recruiting time:

From 2019-09-01 00:00:00 To 2021-08-31 00:00:00

干预措施:

Interventions:

组别:

1

样本量:

150

Group:

1

Sample size:

干预措施:

康柏西普

干预措施代码:

Intervention:

conbercept

Intervention code:

组别:

2

样本量:

150

Group:

2

Sample size:

干预措施:

雷珠单抗

干预措施代码:

Intervention:

Lucentis

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

浙江省 

市(区县):

温州市 

Country:

China

Province:

Zhejiang

City:

单位(医院):

温州医科大学附属眼视光医院 

单位级别:

三级甲等专科医院 

Institution
hospital:

Affiliate Eye hospital of Wenzhou Medical University

Level of the institution:

Tertiary Specialized Hospital

国家:

中国

省(直辖市):

北京 

市(区县):

 

Country:

China

Province:

Beijing

City:

单位(医院):

北京大学人民医院 

单位级别:

三级甲等综合医院 

Institution
hospital:

Peking Universith People Hospital

Level of the institution:

Tertiary Hospital

国家:

中国

省(直辖市):

河南 

市(区县):

 

Country:

China

Province:

He'nan

City:

单位(医院):

河南省立眼科医院 

单位级别:

三级甲等专科医院 

Institution
hospital:

Henan Provincial Eye Hospital

Level of the institution:

Tertiary Specilized Hospital

国家:

中国

省(直辖市):

广东 

市(区县):

 

Country:

China

Province:

Guangdong

City:

单位(医院):

深圳市眼科医院 

单位级别:

二级甲等专科医院 

Institution
hospital:

Shenzhen Eye Hospital

Level of the institution:

Second A Hospital

国家:

中国

省(直辖市):

四川 

市(区县):

 

Country:

Chian

Province:

Sichuan

City:

单位(医院):

四川省人民医院 

单位级别:

三级甲等医院 

Institution
hospital:

Sichuan Provincial People’s Hospital

Level of the institution:

Tertiary A Hospital

国家:

中国

省(直辖市):

天津 

市(区县):

 

Country:

China

Province:

Tianjin

City:

单位(医院):

天津医科大学眼科医院 

单位级别:

三级甲等专科医院 

Institution
hospital:

Eye Hospital of Tianjin Medical University

Level of the institution:

Tertiary A Hospital

测量指标:

Outcomes:

指标中文名:

视力

指标类型:

主要指标

Outcome:

Visual acuity

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

视力

组织:

Sample Name:

Visual acuity

Tissue:

人体标本去向

使用后销毁  

说明

Fate of sample:

Destruction after use  

Note:

征募研究对象情况:

Recruiting status:

尚未开始

Not yet recruiting

年龄范围:

Participant age:

最小 Min age 40 years
最大 Max age years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

Randomization Procedure (please state who generates the random number sequence and by what method):

No

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

公开/Public

盲法:

N/A

Blinding:

N/A

试验完成后的统计结果(上传文件):

Calculated Results after
the Study Completed(upload file):

是否共享原始数据:

IPD sharing

是Yes

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

文章发表后可邮件传递

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

Post the data after publication

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

病例记录表

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

Case Record Form, CRF

数据与安全监察委员会:

Data and Safety Monitoring Committee:

有/Yes

注册人:

Name of Registration:

 2019-07-06 20:33:50